ChondroFiller is not available on the NHS

ChondroFiller is not available on the NHS. No commissioning pathway exists for it in England, Scotland, Wales, or Northern Ireland, and no GP referral will open one.

The reason is more specific than an outright rejection. NICE has not published a technology appraisal for ChondroFiller, which means the treatment sits in an absence of formal guidance rather than having been assessed and declined. The funding landscape could, in principle, change if a formal submission and appraisal process were completed — but no timeline for that exists, and patients should plan on a private pathway today.

In practical terms, this means ChondroFiller is available only on a self-funded basis through private clinics. Waiting for NHS coverage is not a realistic near-term option. The remainder of this article explains what the NHS does offer for cartilage repair, how to access ChondroFiller privately, what it is likely to cost, and whether private medical insurance may contribute — so that patients can make an informed decision rather than simply being told what is not possible.

What the NHS does offer for cartilage repair

Three cartilage repair procedures are currently commissioned by the NHS: Autologous Chondrocyte Implantation (ACI), Matrix-induced ACI (MACI), and Spherox. All three require a formal GP referral to an orthopaedic specialist — patients cannot self-refer, and suitability is determined through secondary-care assessment.

ACI is the most established of these. The Royal National Orthopaedic Hospital at Stanmore has performed over 1,500 cases across fifteen years, making it the UK's leading NHS centre for the procedure. It is well-evidenced and genuinely effective for appropriate candidates. However, it is a two-stage process: cartilage cells are harvested arthroscopically at the first operation, cultured in a laboratory for four to six weeks, then reimplanted at a second operation. Full rehabilitation following the second stage typically takes up to twelve months before a patient can expect a return to normal activity. That pathway demands significant commitment — and it is the procedural burden, rather than any clinical failing, that leads some patients to explore alternatives.

One eligibility point is worth noting for anyone comparing their options: ACI, MACI, Spherox, and ChondroFiller share the same fundamental requirement. None of these treatments is appropriate in the presence of established, generalised osteoarthritis. All four target confirmed focal cartilage defects. A patient told by an NHS orthopaedic specialist that they are not suitable for NHS cartilage repair because of the extent or pattern of their joint disease will, in most cases, also fall outside the eligibility criteria for ChondroFiller. An honest private suitability assessment will reflect that.

Who is a suitable candidate for ChondroFiller

Assuming a focal defect has already been identified — the baseline that separates cartilage repair candidates from those with generalised joint disease — suitability for ChondroFiller then turns on three practical questions: defect size, imaging quality, and access to a clinic equipped for ultrasound-guided delivery.

For the injectable collagen scaffold pathway, the relevant threshold is a defect of approximately 3 cm² or less, confirmed on MRI. Defect size cannot be estimated reliably from symptoms or clinical examination alone. MRI review is the gatekeeping step — not a phone consultation, not an online questionnaire, and not a generic self-referral form. Any clinic that offers a recommendation before reviewing the scan is doing so without the information needed to make it safely.

ChondroFiller is a CE-marked Class III medical device — the same regulatory tier as a surgically implanted implant. It is an acellular injectable collagen scaffold: once placed, it forms a matrix environment that supports the body's own repair processes by recruiting progenitor cells from the surrounding synovium and subchondral bone. This mechanism — acellular matrix-induced chondrogenesis — means the scaffold creates the conditions for endogenous repair rather than introducing cells directly or claiming to regrow cartilage.

Many patients with moderate focal damage, including some who have been managing the problem for several years, do meet these criteria. Age alone is not an exclusion. The determining factors are defect pattern, defect size, and joint status — all of which are visible on a good-quality MRI reviewed by a specialist ahead of any treatment decision.

How to access ChondroFiller privately in the UK

For patients outside London, the practical starting point is straightforward: no GP referral or waiting-list entry is required. ChondroFiller is accessed entirely through private practice, which means a patient can book a suitability consultation directly — without first obtaining a letter from a GP or being placed on an NHS waiting list.

Bringing an existing MRI to that first appointment makes a material difference. Defect size and location must be confirmed on imaging before any treatment recommendation can be made — so if a scan has already been done, the suitability assessment can proceed at the same appointment rather than being deferred to a follow-up visit.

MSK Doctors offers ChondroFiller as an ultrasound-guided outpatient injectable scaffold treatment at its Lincolnshire sites — the Regeneration Hub in Sleaford and the consultation and diagnostics centre in Grantham. Both are consultant-led and CQC-registered. For patients across the East Midlands or the wider non-London catchment, this is the straightforward access route: self-refer, attend with imaging, and receive a suitability assessment without an NHS referral chain or waiting list. Remote video consultations are also available for an initial discussion before travelling — a practical option for anyone coming from further afield.

Patients based in London can access ChondroFiller through London Cartilage Clinic on Harley Street, the group's London arm.

For most patients at this stage, the next question is cost — and whether private medical insurance might cover any part of it.

Costs and whether insurance may cover ChondroFiller

The short answer on cost: ChondroFiller is entirely self-funded, and guide costs in the UK typically range from around £3,000 for a single-unit treatment up to approximately £8,000–£9,500 for larger joints or cases requiring multiple treatment units. The variation reflects two factors — joint size and how many units the MRI assessment indicates are needed.

Box count (one, two, or three units) is confirmed at imaging review, not before it. Any guide figure offered without a reviewed MRI is an estimate that may not reflect the actual treatment required. A personalised cost breakdown, produced after the scan has been assessed, is the reliable figure to plan against.

Private medical insurance

Routine funding from major UK insurers is unlikely: Bupa and AXA do not currently list ChondroFiller as a standard covered benefit. A flat rejection should not, however, be assumed without checking — case-by-case approvals have been reported with Bupa, Aviva, and WPA, so the picture is more nuanced than a blanket exclusion.

Patients pursuing an insurance route should reference the recognised CCSD billing codes when submitting a pre-authorisation request: W3111 (cartilage regeneration with collagen scaffold) and W8500 (arthroscopy, where applicable). Verbal approval from an insurer is not sufficient; written pre-authorisation should be secured before committing to treatment.

What results patients typically see from ChondroFiller

Published data from European clinical experience give a reasonable picture of what to expect. In the knee, IKDC scores improve by approximately 30 points at 12 months — a gain broadly comparable to outcomes reported for ACI and MACI, but achieved without the two-stage surgical pathway those procedures require. Across published case series, 70–85% of patients report meaningful symptom relief. The complication profile is low, and the procedure is generally well tolerated as an outpatient treatment.

These figures come from European clinical experience accumulated over several years; the UK market is at an earlier stage, and large domestic randomised controlled trials have not yet been published. The clinical trajectory, however, is consistent across the available evidence.

Recovery is not immediate. ChondroFiller supports the body's own repair processes through the acellular scaffold mechanism described earlier, and full benefit typically becomes apparent over weeks to months rather than days. Individual results depend on defect characteristics, joint health, and commitment to rehabilitation.

Patients outside London who would like to explore whether ChondroFiller is appropriate can book a consultant assessment without referral at mskdoctors.com. Whether it is the right option — and what a realistic outcome looks like for a given individual — is a question that a clinical assessment is best placed to answer.